The following information accompanied stocks donated to the Bloomington Stock Center by Lenny Rabinow, Harvard Medical School.
According to Genexel, Inc., which isolated it, P{EP}Srrm234G21980 is an insertion at 3L:1664895--1664896 (R6) disrupting the Srrm234 gene. The insertion site lies at the middle the following sequence:
AGCCTAGTAAAGCCAGCGCTTGGATAGCAGCGCCGCAGGACATATAACAGAGGTGAGAAAGCCAGACAAGTCGAACACCACTTGCACTGCAACTGAAATCGATTTTTCGTGTGGTGCAATTGCAGCGTTGGTGGAGCACCCAGTGGCCG
Srrm234G21980 is homozygous lethal.
According to Genexel, Inc., which isolated it, P{EP}CG7974G23564 is an insertion at 3L:1665230--1665231 (R6) in the 5’ UTR of CG7974. The insertion site lies at the middle of the following sequence:
GACTAGATATGCGACAATATGCCGCCCTCAGTGTGACCAGATGACAAATGTCGCCTAAATGCTCCCTAGCTGTCAATTCCACAATGAAGCTAACATGAGTGGATCCTGTTCAAAGCAACGAAGTGGATGTTATCAGTGAAGTGAAAATCGGCGAAACGGGCACACTAATAGCTAAACGTAAACAACAATATTACACTTATTTTATCTTAAGAAATATATAGATTTATTAGTCTAAAATCATGAGCGATGCAGAGGAAACAAAAGCAGAAGCCACCACCAAAGTGTTGTTCAAAAAAGCCGGTCGAAAAAACCTAAGGCAACGCAAGAATTCAGACGAAGAAGAAAAGGAGGAACAGTAAGCCGTCAACAATTAGAAATGAATTAAACTAAAGTGTTCATTTCTATACAGATTAACGCTAGATGAGATTAAAGAACGCCA
P{EP}CG7974G23564 is homozygous viable. It generates rough eyes in combination with a GMR-GAL4 driver, which may reflect ectopic expression of Srrm234.